Delving into the Latest Updates on Zhejiang Hengyan Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Chemical drugs	1

主要目的：研究空腹及餐后状态下单次口服受试制剂氟伐他汀钠缓释片（规格：80mg，浙江恒研医药科技有限公司持证）与参比制剂氟伐他汀钠缓释片（商品名：Lescol® XL，规格：80mg，Novartis Pharmaceuticals Corp持证）在健康成年受试者体内的药代动力学，评价空腹及餐后状态下口服两种制剂的生物等效性。

[Translation]

Main objective: To study the pharmacokinetics of the test preparation fluvastatin sodium sustained-release tablets (specification: 80 mg, licensed by Zhejiang Hengyan Pharmaceutical Technology Co., Ltd.) and the reference preparation fluvastatin sodium sustained-release tablets (trade name: Lescol® XL, specification: 80 mg, licensed by Novartis Pharmaceuticals Corp) in healthy adult subjects after a single oral dose in fasting and fed states, and to evaluate the bioequivalence of the two preparations after oral administration in fasting and fed states.

Start Date16 Oct 2024

Sponsor / Collaborator

Zhejiang Hengyan Pharmaceutical Technology Co., Ltd.

CTR20243423

/ CompletedNot Applicable

随机、开放、单剂量、两制剂、交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次口服富马酸伏诺拉生片后的生物等效性试验

[Translation] A randomized, open-label, single-dose, two-formulation, crossover controlled study to evaluate the bioequivalence of vonoprazan fumarate tablets in Chinese healthy subjects after a single oral dose in the fasting and fed state

主要目的：以浙江恒研医药科技有限公司提供的富马酸伏诺拉生片为受试制剂，按生物等效性试验的有关规定，与Takeda Pharmaceutical Company Limited持证的富马酸伏诺拉生片（商品名：Vocinti®/沃克®，参比制剂）对比在健康人体内的吸收速度及吸收程度，考察两制剂的人体生物等效性。

[Translation]

Main objective: To use vonoprazan fumarate tablets provided by Zhejiang Hengyan Pharmaceutical Technology Co., Ltd. as the test preparation, and compare the absorption rate and extent of vonoprazan fumarate tablets (trade name: Vocinti®/Walker®, reference preparation) certified by Takeda Pharmaceutical Company Limited in healthy humans according to the relevant provisions of bioequivalence studies, and to investigate the bioequivalence of the two preparations in humans.

Start Date10 Oct 2024

Sponsor / Collaborator

Zhejiang Hengyan Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Zhejiang Hengyan Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Hengyan Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Zhejiang Hengyan Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Hengyan Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

Login to view more data